Perspectives on prehypertension

Area of Science:

• Cardiology
• Pharmacology
• Preventive Medicine

Background:

• Prehypertension affects a significant population, carrying a high risk of progression to hypertension.
• Early intervention is crucial to mitigate the long-term cardiovascular consequences of elevated blood pressure.

Purpose of the Study:

• To evaluate the efficacy of candesartan 16 mg in preventing or delaying the onset of hypertension in patients with prehypertension.
• To assess the long-term impact of pharmacologic intervention on hypertension development.

Main Methods:

• The Trial of Preventing Hypertension (TROPHY) involved patients diagnosed with prehypertension.
• Participants received either candesartan 16 mg or a placebo.
• Hypertension incidence was monitored over a 4-year period.

Main Results:

• Candesartan 16 mg demonstrated a 66.3% relative reduction in hypertension incidence at 2 years (26.8% absolute reduction).
• A 15.6% relative reduction in hypertension incidence was observed at 4 years (9.8% absolute reduction) compared to placebo.
• Further analysis is warranted to explore mechanisms involving metabolic syndrome and inflammation.

Conclusions:

• Pharmacologic intervention with candesartan 16 mg is effective in preventing or postponing hypertension in individuals with prehypertension.
• The findings support the development of guidelines for closer monitoring and treatment of prehypertension.
• Early treatment holds significant potential for reducing cardiovascular events.